Immunotherapy and targeted therapy for advanced mouth cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of immunotherapy and targeted therapy to shrink advanced mouth or throat cancer before surgery. It may help make the tumor smaller and easier to remove.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have squamous cell cancer of the mouth or throat.
- The cancer must be stage IVB, meaning it has spread to neck lymph nodes or nearby tissues.
- Your cancer must test positive for PD-L1 and EGFR markers.
- You should not have had radiation therapy to the face or neck before.
- Your tumor must be HPV-negative (for throat cancer).
- You need to be well enough for daily activities (ECOG 0-1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two newer drugs (one targeted therapy, one immunotherapy) given before surgery to shrink mouth cancer and improve outcomes. The goal is to see if combining them is safe and effective for people with stage III-IVA disease.
This trial tests a combination of two drugs given before surgery for advanced mouth or throat cancer. The drugs may help shrink tumors and improve the chance of successful surgery. It is specifically for patients whose cancer has high levels of PD-L1 and EGFR proteins.
This trial tests a combination of two drugs (pucotenlimab and becotatug vedotin) given before surgery for advanced head and neck squamous cell carcinoma. The goal is to shrink tumors and improve outcomes when combined with surgery.
This trial tests a new combination of two drugs for people with advanced head and neck cancer who cannot take standard platinum chemotherapy. The goal is to see if this treatment can help control the cancer and improve outcomes.
This trial tests a new combination of a targeted therapy (EGFR-ADC) and an immunotherapy drug before surgery to shrink and control locally advanced throat cancer. It may help make surgery more effective and reduce the chance of recurrence.
This trial is testing a combination of two drugs (becotatug vedotin and pucotenlimab) given before surgery to shrink recurrent head and neck cancer that has stopped responding to prior immunotherapy and chemotherapy. The goal is to see if this approach helps make the tumor removable and improves outcomes.
Hear when a new Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.